Buscar resultados de ensayos clínicos
Blood Coagulation Disorders, Inherited - 26 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Condición:
Fecha: 2005-09-12 |
Recruiting |
Nombre del estudio: Education Program for Patients Receiving Oral Anticoagulation Condición:
|
Recruiting |
Nombre del estudio: A Gene Transfer Study for Hemophilia A Condición: Hemophilia A Fecha: 2016-12-16 Intervenciones: Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Withdrawn |
Nombre del estudio: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B Condición: Hemophilia B Fecha: 2013-11-14 Intervenciones: Biological: IB1001 Prophylaxis (during Treatment and Conti |
Not yet recruiting |
Nombre del estudio: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients Condición: Antithrombin Deficiency Type 2 Fecha: 2017-03-21 Intervenciones: Drug: ATryn continuous infusion replenish serum thrombin levels |
Completed |
Nombre del estudio: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Condición:
Fecha: 2007-12-21 Intervenciones: Drug: Kogenate (BAY14-2222) One group two treatment schedules, first on-demand then switch to prophylaxi |
Completed |
Nombre del estudio: Epidemiology and Immunology of Hemophilia A Inhibitors Condición:
Fecha: 2000-05-25 |
Terminated |
Nombre del estudio: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery Condición: Thrombophilia Due to Acquired Antithrombin III Deficiency Fecha: 2012-02-07 Intervenciones: Drug: Recombinant antithrombin (rhAT) Subjects will receive an intravenous bolus of 500 units of recombi |
Not yet recruiting |
Nombre del estudio: Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies Condición: Hemophilia Fecha: 2017-05-16 Intervenciones: Other: Non interventionnal study A query form to all concerned patients by each investigating centre wil |
Available |
Nombre del estudio: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors Condición: Hemophilia A Fecha: 2017-05-12 Intervenciones: Biological: Emicizumab Participants will receive emicizumab at a loading dose of 3 milligrams per kilogr |